BioSpace News Archive

Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patients have been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy in Phase 2, KEYNO

- Dr. Rosh Dias appointed Chief Medical Officer - - Dan Spiegelman appointed to Board of Directors - SAN FRANCISCO--( BUSINESS WIRE )-- Spruce Biosciences , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the appointments of Dr. Rosh Dias as Chief Medical Officer and Dan Spiegelman to the board of directors. The appoi

- Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC - Brandon Wustman, Ph.D. promoted to Senior Vice President, R&D MENLO PARK, Calif. & DALLAS--( BUSINESS WIRE )-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for life-limiting respiratory diseases, today announced two key executive appointments. Mu

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products (“DSP”) including DermSecure™ and SIAscopy™. Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products. The supporting teams in sales, training, pro

Initial presentation of data from the Phase 1b part of the LIO-1 trial of lucitanib in combination with nivolumab in advanced metastatic solid tumors New data analyses for Rubraca ® (rucaparib) from the Phase 2 TRITON2 and Phase 3 ARIEL3 studies in patients with metastatic castration-resistant prostate cancer (mCRPC) and recurrent ovarian cancer, respectively First presentation of preclinical data for FAP-2286, a novel peptide-targeted

CANbridge Pharmaceuticals Receives Chinese Marketing Approval for Hunterase ® First Enzyme Replacement Therapy for Hunter Syndrome in China BEIJING & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it received marketing approval from China’s National Medical Products Administration (NMPA) for Hunterase ® (I

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences: Morgan Stanley Virtual 18 th Annual Global Healthcare Conference on Monday, September 14, 2020 at 9:00 a.m. ET. Bank of America Virtu

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months delay for the planned Phase Ib study with ATOR-1015, its tumor-localizing, bispecific CTLA-4 and OX40 antibody developed for treatment of metastatic cancer. As previously communicated, preliminary data from the ongoing Phase

Parvizi Surgical Innovation, LLC (PSI) is pleased to announce an investment and partnership with Coracoid Solutions, LLC (CCS), an early-stage medical device company focused on sports medicine procedures.